Management of menopausal symptoms in breast cancer patients

Maturitas

Volumn 68, Issue 2, 2011, Pages 148-154

  Loibl, S ^a   Lintermans, A ^b   Dieudonne A S ^b   Neven, P ^b  

^a GBG Forschungs GmbH   (Germany)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Antidepressant; Bisphosphonates; Breast cancer; Hot flashes; Menopausal symptoms; Testosterone

Indexed keywords

ANTIDEPRESSANT AGENT; BISPHOSPHONIC ACID DERIVATIVE; CLONIDINE; ESTRADIOL; ESTROGEN; GABAPENTIN; GESTAGEN; GOSERELIN; MEDROXYPROGESTERONE ACETATE; MEGESTROL ACETATE; PAROXETINE; PILOCARPINE; POLYCARBOPHIL; PREGABALIN; SEROTONIN UPTAKE INHIBITOR; TAMOXIFEN; TIBOLONE; VENLAFAXINE;

ACUPUNCTURE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; COGNITION; COGNITIVE DEFECT; DISEASE FREE SURVIVAL; DIZZINESS; DROWSINESS; DRUG EFFICACY; DRUG SAFETY; DYSPAREUNIA; HORMONAL THERAPY; HOT FLUSH; HUMAN; HYPNOSIS; MENOPAUSE; MUSCULOSKELETAL DISEASE; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; OVERALL SURVIVAL; QUALITY OF LIFE; REVIEW; RISK ASSESSMENT; SEXUAL DYSFUNCTION; SOMNOLENCE; UROGENITAL TRACT DISEASE; VAGINAL DRYNESS; VAGINITIS;

ANTIDEPRESSIVE AGENTS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; COGNITION DISORDERS; COMPLEMENTARY THERAPIES; DIPHOSPHONATES; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; FEMALE UROGENITAL DISEASES; HOT FLASHES; HUMANS; MENOPAUSE; MUSCULOSKELETAL DISEASES;

EID: 78651397677     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.maturitas.2010.11.013     Document Type: Review

References (106)

1. R.J. Couzi, K.J. Helzlsouer, and J.H. Fetting Prevalence of menopausal symptoms among women with a history of breast cancer and attitude toward estrogen replacement therapy J Clin Oncol 13 1995 2737 2744
2. E.W. Freeman Associations of depression with the transition to menopause Menopause 17 2010 823 827
3. H. Holmberg, and Anderson HABITS (hormonal replacement therapy after breast cancer - is it safe?), a randomised comparison: trial stopped Lancet 363 2004 453 455
4. L. Holmberg, O.E. Iversen, and C.M. Rudenstam Increased risk of recurrence after hormone replacement therapy in breast cancer survivors J Natl Cancer Inst 100 2008 475 482
5. E. von Schoultz, and L.E. Rutqvist Stockholm Breast Cancer Study Group. Menopausal hormone therapy after breast cancer: the Stockholm randomized trial J Natl Cancer Inst 97 2005 533 535
6. P. Kenemans, N.J. Bundred, and J.M. Foidart Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial Lancet Oncol 10 2009 135 146
7. S.R. Cummings, B. Ettinger, and P.D. Delmas The effects of tibolone in older postmenopausal women N Engl J Med 359 2008 697 708
8. D.L. Hershman, T. Shao, and L.H. Kushi Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer Breast Cancer Res Treat 2010 doi:10.1200/JCO.2009.25.9655.[Epub ahead of print]
9. S.M. McKinlay, and M. Jefferys The menopausal syndrome Br J Prev Soc Med 28 1974 108 115
10. R.M. Goldberg, C.L. Loprinzi, and J.R. O'Fallon Transdermal clonidine for ameliorating tamoxifen-induced hot flashes J Clin Oncol 12 1994 155 158
11. C.L. Loprinzi, J. Sloan, and V. Stearns Newer antidepressants and gabapentin for hot flashes: an individual patient pooled analysis J Clin Oncol 27 2009 2831 2837
12. S. Loibl, K. Schwedler, and G. von Minckwitz Venlafaxine is superior to clonidine as treatment of hot flashes in breast cancer patients - a double-blind, randomized study Ann Oncol 18 2007 689 693
13. V. Stearns, K.L. Beebe, and M. Iyengar Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial JAMA 289 2003 2827 2834
14. C.L. Loprinzi, V. Stearns, and D. Barton Centrally active nonhormonal hot flash therapies Am J Med 12B 2005 118 123
15. D.L. Barton, B.I. LaVasseur, and J.A. Sloan CL. Phase III, placebo-controlled trial of three doses of citalopram for the treatment of hot flashes: NCCTG trial N05C9 J Clin Oncol 28 2010 3278 3283
16. M.F. Wu, S.G. Hilsenbeck, and Y.L. Tham The efficacy of sertraline for controlling hot flashes in women with or at high risk of developing breast cancer Breast Cancer Res Treat 118 2009 369 375
17. Y. Jin, Z. Desta, and V. Stearns CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment J Natl Cancer Inst 97 2005 30 39
18. M.E. Yurcheshen, T. Guttuso Jr., M. McDermott, R.G. Holloway, and M. Perlis Effects of gabapentin on sleep in menopausal women with hot flashes as measured by a Pittsburgh Sleep Quality Index factor scoring model J Womens Health (Larchmt) 18 2009 1355 1360
19. J.N. Brown, and B.R. Wright Use of gabapentin in patients experiencing hot flashes Pharmacotherapy 29 2009 74 81
20. P. Albertazzi, M. Bottazzi, and D.W. Purdie Gabapentin for the management of hot flushes: a case series Menopause 10 2003 214 217
21. C.L. Loprinzi, R. Qin, and E.P. Balcueva Phase III, randomized, double-blind, placebo-controlled evaluation of pregabalin for alleviating hot flashes, N07C1 J Clin Oncol 28 2010 641 647
22. K.J. Pandya, G.R. Morrow, and J.A. Roscoe Gabapentin for hot flashes in 420 women with breast cancer: a randomised double-blind placebo-controlled trial Lancet 366 2005 818 824
23. T. Guttuso Jr., R. Kurlan, and M.P. McDermott Gabapentin's effects on hot flashes in postmenopausal women: a randomized controlled trial Obstet Gynecol 101 2003 337 345
24. K.A. Toulis, T. Tzellos, D. Kouvelas, and D.G. Goulis Gabapentin for the treatment of hot flashes in women with natural or tamoxifen-induced menopause: a systematic review and meta-analysis Clin Ther 31 2009 221 235
25. C.L. Loprinzi, R. Qin, and E.P. Baclueva Phase III, randomized, double-blind, placebo-controlled evaluation of pregabalin for alleviating hot flashes, N07C1 J Clin Oncol 28 2010 641 647
26. C.L. Loprinzi, J.W. Kugler, and D.L. Barton Phase III trial of gabapentin alone or in conjunction with an antidepressant in the management of hot flashes in women who have inadequate control with an antidepressant alone: NCCTG N03C5 J Clin Oncol 25 2007 308 312
27. J.D. Hirata, L.M. Swiersz, and B. Zell Does dong quai have estrogenic effects in postmenopausal women? A double-blind, placebo-controlled trial Fertil Steril 68 1997 981 986
28. B.A. Pockaj, J.G. Gallagher, and C.L. Loprinzi Phase III double-blind, randomized, placebo-controlled crossover trial of black cohosh in the management of hot flashes: NCCTG Trial N01CC1 J Clin Oncol 24 2006 2836 2841
29. D.L. Barton, C.L. Loprinzi, and S.K. Quella Prospective evaluation of vitamin E for hot flashes in breast cancer survivors J Clin Oncol 16 1998 495 500
30. M. Penotti, E. Fabio, and A.B. Modena Effect of soy-derived isoflavones on hot flushes, endometrial thickness, and the pulsatility index of the uterine and cerebral arteries Fertil Steril 79 2003 1112 1117
31. L. Venzke, J.F. Calvert Jr., and B. Gilbertson A randomized trial of acupuncture for vasomotor symptoms in post-menopausal women Complement Ther Med 18 2010 59 66
32. A. Vincent, D.L. Barton, and J.N. Mandrekar Acupuncture for hot flashes: a randomized, shamcontrolled clinical study Menopause 14 2007 45 52
33. E.M. Walker, A.I. Rodriguez, and B. Kohn Acupuncture versus venlafaxine for the management of vasomotor symptoms in patients with hormone receptor-positive breast cancer: a randomized controlled trial J Clin Oncol 28 2010 634 640
34. G. Elkins, J. Marcus, and V. Stearns Randomized trial of a hypnosis intervention for treatment of hot flashes among breast cancer survivors J Clin Oncol 26 2008 5022 5026
35. C.L. Loprinzi, D.L. Barton, and P.E. Carns Stellate-ganglion block: a new treatment for hot flushes? Lancet Oncol 9 June (6) 2008 506 507
36. K. Haest, A. Kumar, and K. Leunen Does the stellate ganglion block reduce severe hot flushes and sleep disturbances in breast cancer patients? Cancer Res 69 2009 [abstract 809]
37. D.R. Pachman, D. Barton, and P.E. Carns Pilot evaluation of a stellate ganglion block for the treatment of hot flashes Support Care Cancer 2010 [Epub ahead of print]
38. J.P. Lydon Stem cells: cues from steroid hormones Nature 465 June (7299) 2010 695 696
39. G. Bertelli, M. Venturini, and L. Del Mastro Intramuscular depot medroxyprogesterone versus oral megestrol for the control of postmenopausal hot flashes in breast cancer patients: a randomized study Ann Oncol 13 2002 883 888
40. C.L. Loprinzi, R. Levitt, and D. Barton Phase III comparison of depomedroxyprogesterone acetate to venlafaxine for managing hot flashes: North Central Cancer Treatment Group Trial N99C7 J Clin Oncol 24 2006 1409 1414
41. M. Hickey, L.I. Emery, J. Gregson, D.A. Doherty, and C.M. Saunders The multidisciplinary management of menopausal symptoms after breast cancer: a unique model of care Menopause 17 2010 727 733
42. L.E. Nachtigall Comparative study: replens versus local estrogen in menopausal women Fertil Steril 6 1994 1178 1180
43. C.L. Loprinzi, S. Abu-Ghazaleh, and J.A. Sloan Phase III randomized double-blind study to evaluate the efficacy of a polycarbophil-based vaginal moisturizer in women with breast cancer J Clin Oncol 15 1997 969 973
44. M. Bygdeman, and M.L. Swahn Replens versus dienoestrol cream in the symptomatic treatment of vaginal atrophy in postmenopausal women Maturitas 23 1996 259 263
45. F.G. Le Veque, and S. Hendrix Oral pilocarpine to treat vaginal xerosis associated with chemotherapy-induced amenorrhea in pre-menopausal women J Clin Oncol 22 2004 8099 [Meeting Abstracts]
46. C.L. Loprinzi, E.P. Balcueva, and H. Liu A phase III randomized, double-blind, placebo-controlled study of pilocarpine for vaginal dryness: NCCTG study N04CA J Clin Oncol 28 2010 9024 [Meeting Abstracts]
47. J.H. Rowland, B.E. Meyerowitz, and C.M. Crespi Addressing intimacy and partner communication after breast cancer: a randomized controlled group intervention Breast Cancer Res Treat 118 2009 99 111
48. S. Palacios Managing urogenital atrophy Maturitas 63 2009 315 318
49. A. Kendall, M. Dowsett, E. Folkerd, and I. Smith Caution: vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors Ann Oncol 17 2006 584 587
50. R. Ponzone, N. Biglia, M.E. Jacomuzzi, F. Maggiorotto, L. Mariani, and P. Sismondi Vaginal oestrogen therapy after breast cancer: is it safe? Eur J Cancer 41 2005 2673 2681
51. N. Biglia, E. Peano, and P. Sgandurra Low-dose vaginal estrogens or vaginal moisturizer in breast cancer survivors with urogenital atrophy: a preliminary study Gynecol Endocrinol 26 6 2010 404 412
52. M. Melisko, H. Rugo, and A. DeLuca A Phase II study of vaginal testosterone cream vs. estring for vaginal dryness or decreased libido in women with early stage breast cancer treated with aromatase inhibitors Cancer Res 69 2009 [Abstract nr 5038]
53. S. Barni, and R. Mondin Sexual dysfunction in treated breast cancer patients Ann Oncol 8 1997 149 153
54. M.E. Melisko, M. Goldman, and H.S. Rugo Amelioration of sexual adverse effects in the early breast cancer patient J Cancer Surviv 4 2010 247 255
55. L. Morales, P. Neven, and D. Timmerman Acute effects of tamoxifen and third-generation aromatase inhibitors on menopausal symptoms of breast cancer patients Anticancer Drugs 15 2004 753 760
56. D. Cella, L. Fallowfield, P. Barker, J. Cuzick, G. Locker, and A. Howell Quality of life of postmenopausal women in the ATAC ("Arimidex", tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for early breast cancer Breast Cancer Res Treat 100 2006 273 284
57. Van Calster B, Van Ginderachter J, Vlasselaer J, et al. Uterine and quality of life changes in postmenopausal women with an asymptomatic tamoxifen-thickened endometrium randomized to continuation of tamoxifen or switching to anastrozole. Menopause; in press, doi: 10.1097/gme. 0b013e3181eb9f14.
58. S.R. Land, D.L. Wickerham, and J.P. Costantino Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial JAMA 295 2006 2742 2751
59. D.L. Barton, D.B. Wender, and J.A. Sloan Randomized controlled trial to evaluate transdermal testosterone in female cancer survivors with decreased libido; North Central Cancer Treatment Group protocol N02C3 J Natl Cancer Inst 99 2007 672 679
60. S.R. Davis, M. Moreau, and R. Kroll Testosterone for low libido in postmenopausal women not taking estrogen N Engl J Med 359 2008 2005 2017
61. C.L. Loprinzi, J.W. Kugler, and J.A. Sloan Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial Lancet 356 2000 2059 2063
62. S.A. Dugan, L.H. Powell, and H.M. Kravitz Musculoskeletal pain and menopausal status Clin J Pain 22 2006 325 331
63. I. Sestak, F. Sapunar, and J. Cuzick Aromatase inhibitor induced carpal tunnel syndrome: results from the ATAC trial J Clin Oncol 27 2009 4961 4965
64. C. Thorne Management of arthralgias associated with aromatase inhibitor therapy Curr Oncol 14 2007 S11 S19
65. R. Coombes, E. Hall, and L. Gibson A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer N Engl J Med 350 2004 1081 1092
66. L. Morales, S. Pans, and R. Paridaens Debilitating musculoskeletal pain and stiffness with letrozole and exemestane: associated tenosynovial changes on magnetic resonance imaging Breast Cancer Res Treat 104 2007 87 91
67. C.A. Presant, L. Bosserman, and T. Young Aromatase inhibitor-associated arthralgia and/or bone pain. Frequency and characterization in non-clinical trial patients Clin Breast Cancer 7 2007 775 778
68. C. Fontaine, A. Meulemans, and M. Huizing Tolerance of adjuvant letrozole outside of clinical trials Breast 17 2008 376 381
69. J. Cuzick, I. Sestak, and D. Cella Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial Lancet Oncol 9 2008 45 53
70. L. Morales, S. Pans, and K. Verschueren Prospective study to assess short-term intra-articular and tenosynovial change in the aromatase inhibitor-associated arthralgia syndrome J Clin Oncol 19 2008 3147 3152
71. I. Sestak, J. Cuzick, and F. Sapunar Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis Lancet Oncol 9 2008 866 872
72. M. Dawson-Basoa, and A.R. Gintzler Involvement of spinal cord delta opiate receptors in the antinociception of gestation and its hormonal simulation Brain Res 757 1997 37 42
73. A. Cvoro, D. Tatomer, and M.K. Tee Selective estrogen receptor-beta agonists repress transcription of proinflammatory genes J Immunol 180 2008 630 636
74. O. Dizdar, L. Özakar, and F.Ü. Malas Sonographic and electrodiagnostic evaluations in patients with AI-related arthralgia J Clin Oncol 27 2009 4956 4961
75. N.L. Henry, D. Pchejetski, and R. A'Hern Inflammatory cytokines and aromatase inhibitor-associated musculoskeletal syndrome: a case-control study Br J Cancer 27 2010 291 296
76. H.J. Burstein, and E.P. Winer Aromatase inhibitors and arthralgias: a new frontier in symptom management for breast cancer survivors J Clin Oncol 25 2007 3797 3799
77. N.L. Henry, J.A. Jacobson, and M. Banerjee A prospective study of aromatase inhibitor-associated musculoskeletal symptoms and abnormalities on serial high-resolution wrist ultrasonography Cancer 116 2010 4360 4367
78. K. Briot, M. Tubiana-Hulin, L. Bastit, I. Kloos, and C. Roux Effect of a switch of aromatase inhibitors on musculoskeletal symptoms in postmenopausal women with hormone-receptor-positive breast cancer: the ATOLL (articular tolerance of letrozole) study Breast Cancer Res Treat 120 2010 127 134
79. K. Crew, J. Capodice, and H. Greenlee Pilot study of acupuncture for the treatment of joint symptoms related to adjuvant aromatase inhibitor therapy in postmenopausal breast cancer patients J Cancer Surviv 1 2007 283 291
80. G. Xepapadakis, P. Ntasiou, and D. Koronarchis New views on treatment of aromatase inhibitor induced arthralgia Breast 19 2010 249 250
81. S. Birrell, and W. Tilley Testosterone undecanoate treatment reduces joint morbidities induced by anastrozole therapy in postmenopausal women with breast cancer: results of a double-blind randomized Phase II trial Cancer Res 69 24 Suppl 2009 [Abstract nr 804]
82. S. Rozenberg, B. Carly, F. Liebens, and C. Antoine Risks of osteoporosis associated with breast cancer treatment: the need to access to preventive treatment Maturitas 64 2009 1 3
83. J.A. Kanis, O. Johnell, A. Oden, A. Dawson, C. De Laet, and B. Jonsson Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds Osteoporos Int 12 2001 989 995
84. A. Sverrisdottir, T. Fornander, H. Jacobsson, E. von Schoultz, and L.E. Rutqvist Bone mineral density among premenopausal women with early breast cancer in a randomized trial of adjuvant endocrine therapy J Clin Oncol 22 2004 3694 3699
85. M. Gnant, B. Mlineritsch, and W. Schippinger Endocrine therapy plus zoledronic acid in premenopausal breast cancer N Engl J Med 360 2009 679 691
86. T.J. Powles, T. Hickish, J.A. Kanis, A. Tidy, and S. Ashley Effect of tamoxifen on bone mineral density measured by dual-energy X-ray absorptiometry in healthy premenopausal and postmenopausal women J Clin Oncol 14 1996 78 84
87. B.E. Hillner, J.N. Ingle, and R.T. Chlebowski American Society of Clinical Oncology 2003. Update on the role of bisphosphonates and bone health issues in women with breast cancer J Clin Oncol 21 2003 4042 4057
88. A. Lipton Should bisphosphonates be utilized in the adjuvant setting for breast cancer? Breast Cancer Res Treat 122 2010 627 636
89. M. Gnant, B. Mlineritsch, and G. Luschin-Ebengreuth Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy Lancet Oncol 9 2008 840 849
90. Hoshi M, Numahata K, Ono K. The impact of zoledronic acid therapy in survival of bladder cancer patients with bone metastasis. 2010 ASCO Annual Meeting; abstract nr 15096.
91. A.M. Brufsky, L.D. Bosserman, and R.R. Caradonna Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results Clin Breast Cancer 9 2009 77 85
92. N.J. Bundred, I.D. Campbell, and N. Davidson Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study results Cancer 101 2008 1001 1010
93. H. Eidtmann, R. de Boer, and N. Bundred Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST study Ann Oncol 2010 [Epub ahead of print]
94. K. Ellis, H.G. Bone, and R. Chlebowski Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer J Clin Oncol 26 2008 4875 4882
95. V. Jenkins, V. Shilling, and G. Deutsch A 3-year prosepctive study of the effects of adjuvant treatments on cognition in women with early stage breast cancer Br J Cancer 94 2006 828 834
96. J.S. Wefel, A.K. Saleeba, A.U. Buzdar, and C.A. Meyers Acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancer Cancer 116 2010 3348 3356
97. T. Matsuda, T. Takayama, M. Tashiro, Y. Nakamura, Y. Ohashi, and K. Shimozuma Mild cognitive impairment after adjuvant chemotherapy in breast cancer patients - evaluation of appropriate research design and methodology to measure symptoms Breast Cancer 12 2005 279 287
98. S.A. Shumaker, C. Legault, and L. Kuller Women's Health Initiative Memory Study. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study JAMA 291 2004 2947 2958
99. S.M. Phillips, and B.B. Sherwin Effects of estrogen on memory function in surgically menopausal women Psychoneuroendocrinology 17 1992 485 495
100. W.A. Rocca, J.H. Bower, and D.M. Maraganore Increased risk of cognitive impairment or dementia in women who underwent oophorectomy before menopause Neurology 69 2007 1074 1083
101. V. Natale, P. Albertazzza, and N. Missiroli Effects of raloxifene on mood, sleep, libido and cognitive function in postmenopausal healthy women: a pilot study Maturitas 48 2004 59 63
102. K. Yaffe, K. Krueger, and S. Sarkar Cognitive function in postmenopausal women treated with raloxifene N Engl J Med 344 2001 1207 1213
103. C. Legault, P.M. Maki, and S.M. Resnick Effects of tamoxifen and raloxifene on memory and other cognitive abilities: cognition in the study of tamoxifen and raloxifene J Clin Oncol 2731 2009 5144 5152
104. E.S. Greenwald Organic mental changes with fluorouracil (letter) J Am Med Assoc 235 1976 248 249
105. S. Kohli, S.G. Fisher, and Y. Tra The effect of modafinil on cognitive function in breast cancer survivors Cancer 115 2009 2605 2616
106. M. Poppelreuter, J. Weis, and H.H. Bartsch Effects of specific neuropsychological training programs for breast cancer patients after adjuvant chemotherapy J Psychosoc Oncol 27 2009 274 296